Long-Term Efficacy in AMD of Rheopheresis in North America

Inclusion Criteria: * Must have participated in treatment arm of MIRA-1 trial and completed 4 treatments and 6 and 9 month follow up visits. * Dry AMD in at least one eye. * Available for study duration of 12 months. * Weigh \>110 lbs. * If on lipid-lowering medication must remain on for duration of trial. If not, must agree to not initate during trial. * Normal Pt/ PTT. If on coumadin, at the discretion of the investigator. * Must be highly motivated, alert and oriented, and able to provide consent. * Agree to discontinue current ocular vitamin regimen and take uniform supplement provided by the sponsor. Exclusion Criteria: * Both eyes wet AMD. * Condition limiting view of the fundus. * Poor general health or unstable diseases. * HCT \< 35%, evidence of active bleeding, platelet count \<100000 K/uL, prolonged Pt/ PTT, or significant coagupapathies. * significant cardiac problems. * Uncontrolled hypertension. * History of CVA of TIA within a year. * Significant hepatic, renal, or pulmonary disease, or insulin dependent diabetes. * Allergy to fluorescein sodium and indocyanine green (ICG), heparin, ACDA, local anesthetics, or adhesive tape. * Pregnant or breastfeeding women, or women of childbearing potential not using chemical or mechanical contraception. * Investigation trial within 30 days. * Major surgery within 30 days. * Unwilling to adhere to visit schedule. * Unstable medical of psychological condition.